Predict your next investment

BioFactura company logo
HEALTHCARE | Drug Development
biofactura.com

See what CB Insights has to offer

Founded Year

2003

Stage

Series B | Alive

Total Raised

$7.8M

Last Raised

$6M | 2 yrs ago

About BioFactura

BioFactura develops and commercializes biodefense drugs, client-selected drugs, and high-value biosimilars (i.e., follow-on biologics or generic biopharmaceuticals) using its patented StableFast Biomanufacturing Platform, the optimal choice for bringing these drugs to market with faster, lower cost, superior-quality manufacture.

BioFactura Headquarter Location

8435 Progress Dr. Suite Z

Frederick, Maryland, 21701,

United States

301-315-8002

Latest BioFactura News

BioFactura inks material transfer agreement with Rani Therapeutics for Stelara biosimilar

Sep 16, 2021

Rani has agreed to evaluate BFI-751 in its RaniPill capsule, a novel, proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. Senior Editor BioFactura , a leading developer of high-value biosimilar and biodefense drugs using its patented StableFast platform, announced an agreement with Rani to assess its Ustekinumab biosimilar (BFI-751) in combination with Rani’s RaniPill platform. BFI-751 is being developed by BioFactura Australia, a subsidiary of BioFactura, as a biosimilar drug to Stelara (ustekinumab), a biologic medication used to treat people diagnosed with Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis. Stelara is an immunosuppressant that reduces the effects of inflammatory proteins within the body. BFI-751 employs BioFactura’s StableFast technology, a novel platform that allows for the faster generation of fingerprint-like copies of the targeted reference drug. Under terms of the material transfer agreement, Rani has agreed to evaluate BFI-751 in its RaniPill capsule, a novel, proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The RaniPill capsule is designed to be a pain-free alternative for delivering large molecule chronic disease treatments that are typically administered via injection. Rani will conduct preclinical studies to determine whether BFI-751 can successfully be delivered into the bloodstream, when administered orally via the RaniPil capsule. “With the prevalence of autoimmune diseases across the globe, it is important to provide new options to treat patients in innovative ways," said Dr. Darryl Sampey, BioFactura’s president and CEO. "The combination of BFI-751 and Rani’s delivery platform could provide an alternative treatment for debilitating disorders and improve patient compliance with an easy-to-swallow option.” Dr. Jeffrey Hausfeld, chief medical officer and chairman of the BioFactura board of directors said, “It’s very exciting being on the cutting edge of technology. Bringing together our Stelara biosimilar with Rani's oral platform is a good example of BioFactura’s mission to continuously innovate, provide patients with high quality products, and offer improved value and accessibility.”

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing BioFactura

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

BioFactura is included in 2 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

B

Biopharmaceuticals

5,732 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

BioFactura Patents

BioFactura has filed 3 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • Molecular biology
  • Coagulation system
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/27/2016

9/15/2020

Molecular biology, Biotechnology, Genetics, Genetic engineering, Gene delivery

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

4/27/2016

00/00/0000

00/00/0000

Grant Date

9/15/2020

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Related Topics

Molecular biology, Biotechnology, Genetics, Genetic engineering, Gene delivery

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

BioFactura Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

BioFactura Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.